WO2010083722A1 - A process for one-pot synthesis of corey lactone - Google Patents
A process for one-pot synthesis of corey lactone Download PDFInfo
- Publication number
- WO2010083722A1 WO2010083722A1 PCT/CN2010/000058 CN2010000058W WO2010083722A1 WO 2010083722 A1 WO2010083722 A1 WO 2010083722A1 CN 2010000058 W CN2010000058 W CN 2010000058W WO 2010083722 A1 WO2010083722 A1 WO 2010083722A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- reaction
- formula
- preparation
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
- C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
Definitions
- This patent relates to a method for synthesizing Corey lactone, a key intermediate in the total synthesis of prostaglandins. Background technique ,
- Prostaglandins are an important endogenous physiologically active natural product, which is extremely low in biological tissues. It was discovered by von Enler in 1930, and its skeleton is composed of a five-membered ring.
- the carboxylic acid of 20 carbon atoms according to the structural difference of the five-membered ring, the natural prostate can be of the PGA, PGB, PGC, PGE and PGF types, prostaglandins on the reproductive system, nervous system, respiratory system, endocrine and other systems. has an effect.
- PGE 2 the drug for the induction of labor
- PGE dinoprostone
- glaucoma treatments such as Travoprost and Latanoprost.
- Corey lactone acid of formula II 5-hydroxy-hexahydro-2-oxo-277-cyclopenta[b]furan-4-carboxylic acid, the molecular formula is: C 8 H 1() 0 5 , the molecular weight is 186.05.
- the racemate of Corey lactone is resolved by S-((x)-phenethylamine (Liu Zhizhen et al., Organic Chemistry, 1985, 371-372), which readily forms an anti-imiding salt, is easily crystallized, and can be non- The same amount of salt, more economical when split, the free optical pure (-)-Corey lactone acid can be used to synthesize various prostaglandins (PGs).
- the Corey lactone acid represented by the formula II is mainly obtained by oxidation reaction of 2-halo-5-oxobicyclo[2.2.1]heptane-7-carboxylic acid represented by the formula I and an ester derivative thereof. 6-Chloro- 3- oxo-2-oxabicyclo[3.2.1]octane-8-carboxylic acid and its ester derivative are shown in hydrazine, and then hydrolyzed by ring opening and cyclized.
- the main difference between the existing Corey lactone acid preparation methods is that the oxidizing agent used in the first oxidation reaction is different, and can be roughly classified into the following two categories:
- the oxidation reaction has a single step yield of 70%;
- step-by-step synthesis 3 steps can be completed using 2 or even 3 reaction vessels.
- the synthesis of Corey lactone acid, the separation and purification of each step is troublesome;
- M-chloroperoxybenzoic acid and peracetic acid are easy to release oxygen. It is unsafe to store and transport. The higher the purity, the greater the risk, especially the high concentration of peracetic acid, which is extremely explosive;
- the object of the present invention is to overcome the deficiencies of the above-mentioned techniques and to provide a novel process for synthesizing Corey lactone acid by a one-pot method.
- the present invention uses a potassium persulfate preparation (OXONE) as an oxidant, and the one-pot process for preparing the Corey lactone acid of the formula II includes the following steps:
- the method for preparing a compound of formula III using the potassium peroxodisulfate formulation (OXONE) as an oxidizing agent comprises the following steps:
- the compound of the formula III can be obtained by a conventional method of treatment and purification. Compared with the prior art, the advantages of the invention are as follows:
- the oxidizing agent potassium persulfate preparation (OXO E) used in the new process described in the present invention is one-tenth the price of m-chloroperoxybenzoic acid, so that the production cost can be greatly reduced;
- Figure 1 shows dinoprostone (PGE 2 ), alprostadil (PGE ⁇ travoprost) (Travoprost) and the structure of Latanoprost;
- Figure 2 shows the 2-chloro-5-oxobicyclo[2.2.1]heptane-7-carboxylic acid of formula I and its ester derivative obtained by oxidation to give 6-chloro- represented by formula III.
- the structure of the compound prepared by the method of the present invention has been confirmed by hydrogen spectrum, carbon spectrum and mass spectrometry, and the structure is correct.
- Corey lactone is the same term as Corey lactone acid.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
一锅煮方法合成 COREY内酯的工艺 技术领域 Process for synthesizing COREY lactone by one-pot method
本专利涉及前列腺素类化合物全合成中关键中间体 Corey内酯的合 成方法。 背景技术 , This patent relates to a method for synthesizing Corey lactone, a key intermediate in the total synthesis of prostaglandins. Background technique ,
前列腺素 (Prostaglandins, PGs)是一类重要的内源性生理活性天然 产物, 在生物组织中含量极低, 其于 1930年由尤勒(von Enler)发现, 其骨架是为含一个五元环的 20个碳原子的羧酸,根据五元环的结构差 异,天然的前列腺可为 PGA、 PGB、 PGC、 PGE和 PGF等类型、 前列 腺素对生殖系统, 神经系统, 呼吸系统, 内分泌等系统都有作用。 Prostaglandins (PGs) are an important endogenous physiologically active natural product, which is extremely low in biological tissues. It was discovered by von Enler in 1930, and its skeleton is composed of a five-membered ring. The carboxylic acid of 20 carbon atoms, according to the structural difference of the five-membered ring, the natural prostate can be of the PGA, PGB, PGC, PGE and PGF types, prostaglandins on the reproductive system, nervous system, respiratory system, endocrine and other systems. has an effect.
通过对天然前列腺素的研究, 以及对其结构改造出现了一大批前 列腺素类药物, 用途十分广泛, 如用于引产的药物地诺前列酮 (PGE2), 用于心血管疾病治疗的前列地尔 (PGE 用于青光眼治疗的药物曲伏前 列腺素(Travoprost)与拉坦前列腺素(Latanoprost)等等。 A large number of prostaglandins have been developed through the study of natural prostaglandins and their structural modifications. For example, the drug for the induction of labor, dinoprostone (PGE 2 ), is used in the forefront of cardiovascular disease treatment. (PGE is used for glaucoma treatments such as Travoprost and Latanoprost.
图 1 figure 1
自从 RJ. Corey完成天然的前列腺素全合成至现在, 已 30余年了。 在此期间有机合成化学家和生物化学家们做了大量工作,发展了多条全 合成路线, 所用的起始原料多种多样, 有环戊二烯、 桥式双环戊二烯、 降冰片二烯、茚满醇、 D-葡萄糖以及 L-赤癣糖等。这些路线中的关键中 间体有 Corey'醇、 γ-内酯物、双环己烷等。其中 Ε丄 Corey在 US 3992438 公开的的路线以降冰片二烯为原料合成重要中间体 Corey内酯化合物, 该路线反应条件温和、步骤少, 因此具有一定的优势, 已成为制备天然 前列腺素及其衍生物的常用路线之一, 式 ΙΠ化合物(图 2)所示的 6-氯 -3-氧代 -2-氧杂双环 [3.2.1]辛烷 -8-羧酸及其酯类衍生物与式 II所示的化 合物 Corey内酯酸皆是本条路线中的关键中间体。 It has been more than 30 years since RJ. Corey completed the natural synthesis of prostaglandins. During this period, organic synthetic chemists and biochemists have done a lot of work and developed a number of fully synthetic routes using a variety of starting materials, including cyclopentadiene, bridged dicyclopentadiene, and norbornene. Alkene, indanol, D-glucose, and L-erythrose. The key intermediates in these routes are Corey' alcohol, γ-lactone, bicyclohexane, and the like. Among them, rey Corey's route disclosed in US 3992438 uses norbornadiene as a raw material to synthesize an important intermediate Corey lactone compound. This route has mild reaction conditions and few steps, so it has certain advantages and has become a natural preparation. One of the common routes for prostaglandins and their derivatives, 6-chloro-3-oxo-2-oxabicyclo[3.2.1]octane-8-carboxylic acid represented by the hydrazine compound (Fig. 2) Both ester derivatives and the compound of formula II, Corey lactone, are key intermediates in this route.
式 II所示的 Corey内酯酸化学名: 5-羟基 -六氢 -2-氧代 -277-环戊并 [b] 呋喃 -4-羧酸, 分子式为: C8H1()05, 分子量为 186.05。 Corey 内酯酸的 消旋体以 S-((x)-苯乙胺拆分(刘志煜等, 有机化学, 1985, 371-372), 容易形成非 映异构盐, 易析晶, 并且可以非等量成盐, 大量拆分时比 较经济, 游离出的光学纯(-) -Corey 内酯酸可用于合成各种前列腺素类 化合物 (PGs)。 The trade name of Corey lactone acid of formula II: 5-hydroxy-hexahydro-2-oxo-277-cyclopenta[b]furan-4-carboxylic acid, the molecular formula is: C 8 H 1() 0 5 , the molecular weight is 186.05. The racemate of Corey lactone is resolved by S-((x)-phenethylamine (Liu Zhizhen et al., Organic Chemistry, 1985, 371-372), which readily forms an anti-imiding salt, is easily crystallized, and can be non- The same amount of salt, more economical when split, the free optical pure (-)-Corey lactone acid can be used to synthesize various prostaglandins (PGs).
目前式 II所示的 Corey 内酯酸主要由式 I所示的 2-卤代 -5-氧代双 环 [2.2.1]庚烷 -7-羧酸及其酯类衍生物通过氧化反应得到式 ΠΙ所示的 6- 氯 _3_氧代 _2-氧杂双环 [3.2.1]辛烷 -8-羧酸及其酯类衍生物,然后再水解开 环, 环合制得。 The Corey lactone acid represented by the formula II is mainly obtained by oxidation reaction of 2-halo-5-oxobicyclo[2.2.1]heptane-7-carboxylic acid represented by the formula I and an ester derivative thereof. 6-Chloro- 3- oxo-2-oxabicyclo[3.2.1]octane-8-carboxylic acid and its ester derivative are shown in hydrazine, and then hydrolyzed by ring opening and cyclized.
图 2 figure 2
现有 Corey内酯酸制备方法主要区别在于第一步氧化反应所采用氧 化剂不同, 大致可分为如下两类: The main difference between the existing Corey lactone acid preparation methods is that the oxidizing agent used in the first oxidation reaction is different, and can be roughly classified into the following two categories:
1. 以间氯过氧苯甲酸(m-CPBA)作为氧化剂,氧化反应单步收率 70%; 1. With m-perfluorobenzoic acid (m-CPBA) as an oxidizing agent, the oxidation reaction has a single step yield of 70%;
(Tetrahedron, 37, 1981, 411-420) (Tetrahedron, 37, 1981, 411-420)
2. 以 40%或 1M过氧乙酸(CH3COOOH) 作为氧化剂, 氧化反应单步 收率 60-70%。 (US 3992438 & Synthesis, 1985, 5, 491-492) 现有方法制备式 II所示的 Corey内酯酸存在以下不足: 2. With 40% or 1M peracetic acid (CH 3 COOOH) as the oxidant, the oxidation reaction yield is 60-70% in a single step. (US 3992438 & Synthesis, 1985, 5, 491-492) Existing methods for preparing Corey lactone acids of Formula II have the following disadvantages:
1. 采用分步合成法, 3步反应需使用 2个甚至 3个反应容器才能完成 Corey内酯酸的合成, 每一步的分离纯化比较麻烦; 1. Using step-by-step synthesis, 3 steps can be completed using 2 or even 3 reaction vessels. The synthesis of Corey lactone acid, the separation and purification of each step is troublesome;
2. 氧化反应中所采用的间氯过氧苯甲酸国产质量一般, 而进口价格较 贵, 高浓度过氧乙酸难以购得; 2. The domestic quality of m-chloroperoxybenzoic acid used in the oxidation reaction is generally high, while the import price is relatively expensive, and high-concentration peracetic acid is difficult to purchase;
3. 间氯过氧苯甲酸与过氧乙酸易释放氧, 储存、 运输皆不安全, 纯度 越高, 危险性越大, 特别是高浓度的过氧乙酸, 极易爆炸; 3. M-chloroperoxybenzoic acid and peracetic acid are easy to release oxygen. It is unsafe to store and transport. The higher the purity, the greater the risk, especially the high concentration of peracetic acid, which is extremely explosive;
4. 间氯过氧苯甲酸反应后生成间氯苯甲酸与目标产物分离困难, 硅胶 柱层析分离效果好, 但需要大量洗脱溶剂剂, 成本高, 使工业化大生产 受到限制; · . 4. The reaction of m-chloroperbenzoic acid to form m-chlorobenzoic acid is difficult to separate from the target product. The separation of silica gel column chromatography is good, but it requires a large amount of solvent to be eluted. The cost is high, which limits the industrial production.
5. 以间氯过氧苯甲酸或过氧乙酸作为氧化剂, 收率皆不是很高。 发明内容 5. With m-chloroperoxybenzoic acid or peracetic acid as the oxidant, the yield is not very high. Summary of the invention
本发明的目的在于克服上述技术存在的不足,提供一种一锅煮方法 合成 Corey内酯酸的新工艺。 本发明以过硫酸氢钾制剂 (OXONE) 作为氧化剂, 制备式 II所示 Corey内酯酸的一锅煮工艺包括如下步骤: SUMMARY OF THE INVENTION The object of the present invention is to overcome the deficiencies of the above-mentioned techniques and to provide a novel process for synthesizing Corey lactone acid by a one-pot method. The present invention uses a potassium persulfate preparation (OXONE) as an oxidant, and the one-pot process for preparing the Corey lactone acid of the formula II includes the following steps:
1. 将式 I所示的 2-卤代 -5-氧代双环 [2.2.1]庚垸 -7-羧酸及其酯类衍生物 溶于反应溶剂中, 在 0°C〜100°C条件下分批加入过硫酸氢钾制剂 1. The 2-halo-5-oxobicyclo[2.2.1]heptan-7-carboxylic acid of formula I and its ester derivative are dissolved in a reaction solvent at 0 ° C to 100 ° C. Potassium persulfate preparation in batches under conditions
(OXONE) 粉末; (OXONE) powder;
2. TLC板检测原料消失后, 加入亚硫酸氢钠淬灭, 继续搅拌反应; 2. After the TLC plate detects the disappearance of the raw materials, it is quenched by adding sodium hydrogen sulfite, and the stirring reaction is continued;
3. 滴入碱性水溶液, 至 PH值: 8~12, 继续搅拌反应 10分钟〜 12小时;3. Drip the alkaline aqueous solution to PH value: 8~12, continue to stir the reaction for 10 minutes~12 hours;
4. 滴入酸性水溶液, 调 PH值: 1〜6, 继续搅拌反应 10分钟〜 12小时;4. Drip the acidic aqueous solution, adjust the pH value: 1~6, continue to stir the reaction for 10 minutes~12 hours;
5. 待反应结束后采用常规方法处理、 提纯后即可得到所需的式 II所示 的 Corey内酯酸。 本发明以过硫酸氢钾制剂 (OXONE) 作为氧化剂制备式 III所示化 合物的方法包括如下步骤: 5. After the reaction is completed, it can be treated by conventional methods and purified to obtain the desired formula II. Corey lactone acid. The method for preparing a compound of formula III using the potassium peroxodisulfate formulation (OXONE) as an oxidizing agent comprises the following steps:
1. 将式 I所示的 2-卤代 -5-氧代双环 [2.2.1]庚烷 -7-羧酸及其酯类衍生物 溶于反应溶剂中, 加入或不加入 4-丁基溴化铵, 搅拌, 分批加入过硫酸 氢钾制剂 (OXO E), 0〜100Ό搅拌 1〜3天; 1. Dissolving 2-halo-5-oxobicyclo[2.2.1]heptane-7-carboxylic acid of formula I and its ester derivative in a reaction solvent with or without addition of 4-butyl Ammonium bromide, stirred, batchwise added potassium persulfate preparation (OXO E), 0~100Ό stirred for 1~3 days;
2. 待反应结束后采用常规方法处理、提纯后即可得到式 III所示化合物。 本发明与现有技术相比, 其优点如下: 2. After the reaction is completed, the compound of the formula III can be obtained by a conventional method of treatment and purification. Compared with the prior art, the advantages of the invention are as follows:
1. 使得 Corey内酯酸的合成可置于同一反应容器中完成, 避免了中间 体后处理及转移带来的产品损失, 简化了操作, 减少了使用溶剂的种类 和数量, 减少了工业化时的设备投资, 降低了工厂生产时的生产成本; 1. The synthesis of Corey lactone can be completed in the same reaction vessel, avoiding product loss caused by intermediate post-treatment and transfer, simplifying operation, reducing the type and quantity of solvent used, and reducing industrialization. Equipment investment, reducing the production cost of the factory production;
2.本发明中所述的新工艺中所使用的氧化剂过硫酸氢钾制剂(OXO E) 的价格为间氯过氧苯甲酸的十分之一, 因此可大副度降低生产成本;2. The oxidizing agent potassium persulfate preparation (OXO E) used in the new process described in the present invention is one-tenth the price of m-chloroperoxybenzoic acid, so that the production cost can be greatly reduced;
3. 0 0^氧化剂的化学性质比较稳定, 不易变质, 室温存放或运输安 全, 不易爆炸, 有利于工业化大生产; 3. 0 0 ^ The chemical properties of the oxidant are relatively stable, not easy to deteriorate, safe to store or transport at room temperature, not easy to explode, which is conducive to industrial large-scale production;
4. 一锅煮反应及后处理过程中, 主要生成一些无机钠盐, 钾盐, 对环 境污染小; 4. In the process of one-pot boiling reaction and post-treatment, some inorganic sodium salts and potassium salts are mainly formed, which have little environmental pollution;
5. 本反应的收率比使用间氯过氧苯甲酸或过氧乙酸作为氧化剂有显著 提高。 附图说明: 5. The yield of this reaction is significantly higher than the use of m-chloroperoxybenzoic acid or peracetic acid as the oxidant. BRIEF DESCRIPTION OF THE DRAWINGS:
图 1 表示地诺前列酮 (PGE2)、 前列地尔 (PGE^ 曲伏前列腺素 (Travoprost)与拉坦前列腺素(Latanoprost)的结构; Figure 1 shows dinoprostone (PGE 2 ), alprostadil (PGE^ travoprost) (Travoprost) and the structure of Latanoprost;
图 2表示由式 I所示的 2-卤代 -5-氧代双环 [2.2.1]庚烷 -7-羧酸及其酯 类衍生物通过氧化反应得到式 III所示的 6-氯 -3-氧代 -2-氧杂双环 [3.2.1] 辛烷 -8-羧酸及其酯类衍生物,然后再水解开环,环合制得 Corey内酯酸 的过程。 本发明所采用方法制备的化合物, 其结构已经氢谱、碳谱、质谱证 实, 结构是正确的。本发明中, Corey内酯与 Corey内酯酸是同一术语。 Figure 2 shows the 2-chloro-5-oxobicyclo[2.2.1]heptane-7-carboxylic acid of formula I and its ester derivative obtained by oxidation to give 6-chloro- represented by formula III. 3-oxo-2-oxabicyclo[3.2.1]octane-8-carboxylic acid and its ester derivatives, which are then hydrolyzed to ring-opening and cyclized to give Corey lactone acid. The structure of the compound prepared by the method of the present invention has been confirmed by hydrogen spectrum, carbon spectrum and mass spectrometry, and the structure is correct. In the present invention, Corey lactone is the same term as Corey lactone acid.
本发明可由下列实施例得到进一步阐述, 但并不是限制本发明。 具体实施方式: The invention is further illustrated by the following examples, which are not intended to limit the invention. detailed description:
实施例 1 Example 1
6-氯 -3-氧代 -2-氧杂双环 [3.2.1]辛焼 -8-羧酸甲酯的制备 Preparation of 6-chloro-3-oxo-2-oxabicyclo[3.2.1]methyl octyl-8-carboxylate
于反应瓶依次加入 2-卤代 -5-氧代双环 [2.2.1]庚烷 -7-羧酸甲酯 5g, 4-丁基溴化铵 20mg, CH2C12 50ml, 水 50ml, 再分批加入 oxone 22.5g, 搅拌反应 48小时, TLC板检测至无明显原料残余,抽滤,滤饼以 C¾C12 10mlx2洗涤, 滤液以 NaHS03饱和溶液 30mlx2洗涤, 分出有机相, 以 无水硫酸钠千燥, 抽滤, 蒸干, 以水重结晶得白色晶体。 实施例 2 5 g of 2-halo-5-oxobicyclo[2.2.1]heptane-7-carboxylic acid methyl ester, 20 mg of 4-butylammonium bromide, 50 ml of CH 2 C1 2 and 50 ml of water were added to the reaction flask. 22.5g of oxone was added in portions, the reaction was stirred for 48 hours, and the TLC plate was detected to have no obvious residue of the raw material. The filter cake was washed with C3⁄4C1 2 10 ml× 2 , and the filtrate was washed with 30 mL× 2 of a saturated solution of NaHS0 3 to separate the organic phase to anhydrous sulfuric acid. The sodium is dried, suction filtered, evaporated to dryness, and recrystallized from water to give white crystals. Example 2
6-氯 -3-氧代 -2-氧杂双环 [3.2.1】辛烷 -8-羧酸的制备 Preparation of 6-chloro-3-oxo-2-oxabicyclo[3.2.1]octane-8-carboxylic acid
于反应瓶依次加入 2-卤代 -5-氧代双环 [2.2.1]庚垸 -7-羧酸 5g, 丙酮- 水混合溶液 50ml, 再分批加入 oxone 22.5g, 搅拌反应过夜, TLC板检 测至无明显原料残余, 抽滤, 滤饼以丙酮 10mlx2洗涤, 滤液减压蒸除 甲醇, 以乙酸乙酯 100mlx3 萃取, 合并有机层以饱和食盐水 100mlx2 洗涤, 分出有机层以无水硫酸钠干燥过夜, 抽滤, 蒸干, 丙酮-乙醚重 结晶得白色晶体。 实施例 3 5 g of 2-halo-5-oxobicyclo[2.2.1]heptan-7-carboxylic acid, 50 ml of acetone-water mixed solution were added to the reaction flask, and then oxone 22.5 g was added in portions, and the reaction was stirred overnight, TLC plate. No obvious residue of raw materials was detected, suction filtration, filter cake was washed with acetone 10 ml×2, and the filtrate was distilled off under reduced pressure. The mixture was extracted with EtOAc (EtOAc)EtOAc.EtOAc. Example 3
5-羟基 -六氢 -2-氧代 环戊并 [b]呋喃 -4-羧酸的制备 Preparation of 5-hydroxy-hexahydro-2-oxocyclopenta[b]furan-4-carboxylic acid
于反应瓶依次加入 2-氯 -5-氧代双环 [2.2.1]庚烷 -7-羧酸 80 g, 甲醇 500 ml后, 再逐渐加入 OXONE 270 g, 室温搅拌反应, TLC检测至无 明显原料残余, 加入亚硫酸氢钠淬灭反应, 滴加 10%NaOH碱化, 继续 反应, 加入浓盐酸调 PH值酸性, 反应液减压浓缩, 以 THF提取, 分出 有机层,无水 酸钠干燥,抽滤蒸干得白色固体, 乙醚洗涤得目标产品。 实施例 4 After adding 80 g of 2-chloro-5-oxobicyclo[2.2.1]heptane-7-carboxylic acid to the reaction flask, 500 ml of methanol, and then gradually adding OXONE 270 g, the reaction was stirred at room temperature, and the TLC was detected to be insignificant. The residue of the raw material is quenched by adding sodium hydrogen sulfite, alkalized by adding 10% NaOH, the reaction is continued, concentrated hydrochloric acid is added to adjust the pH value, the reaction liquid is concentrated under reduced pressure, extracted with THF, and the organic layer is separated, sodium anhydrous Dry, suction and dry to give a white solid. Example 4
5-羟基 -六氢 -2-氧代 -2 环戊并 [b]呋喃 -4-羧酸的制备 Preparation of 5-hydroxy-hexahydro-2-oxo-2 Cyclopenta[b]furan-4-carboxylic acid
于反应瓶依次加入 2-氯 -5-氧代双环 [2.2.1]庚垸 -7-羧酸甲酯 57g, 丙 酮-水混合液 2500 ml后, 再逐渐加入 OXONE 180 g, 室温搅拌反应, TLC检测至无明显原料残余,加入亚硫酸氢钠淬灭反应,继续搅拌反应, 滴加 10%NaOH碱化,继续反应,加入浓盐酸调至酸性,继续搅拌反应, 反应液减压浓缩, 以 THF:AcOEt(l:l,V/V)提取, 无水硫酸钠干燥, 抽滤 蒸干得白色固体, 丙酮-石油醚重结晶得白色晶体。 实施例 5 To the reaction flask, 57 g of 2-chloro-5-oxobicyclo[2.2.1]heptan-7-carboxylate methyl ester and 2500 ml of acetone-water mixture were added successively, and then OXONE 180 g was gradually added thereto, and the reaction was stirred at room temperature. TLC detected no obvious residue of raw materials, quenched the reaction by adding sodium hydrogen sulfite, stirring the reaction, adding alkalization with 10% NaOH, continuing the reaction, adding concentrated hydrochloric acid to adjust the acidity, stirring the reaction, and concentrating the reaction solution under reduced pressure. THF:AcOEt (1:1, V/V) was extracted, dried over anhydrous sodium sulfate and evaporated to dryness to afford white crystals. Example 5
5-羟基 -六氢 -2-氧代 -2 环戊并 [b]呋喃 -4-羧酸的制备 Preparation of 5-hydroxy-hexahydro-2-oxo-2 Cyclopenta[b]furan-4-carboxylic acid
于反应瓶依次加入 2-氯 -5-氧代双环 [2.2.1]庚烷 -7-羧酸 53 g, 丙酮- 水混合溶剂 2000 ml后,再逐渐加入 OXONE 150 g,室温搅拌反应, TLC 检测至无明显原料残余, 加入 NaHS03淬灭反应, 反应液升温, 蒸除部 分溶剂后继续搅拌, 降温, 滴加 10% NaOH调至碱性, 继续反应, 加入 浓盐酸调至酸性, 继续搅拌, 减压浓缩反应液, 以 EtOAc提取, 无水 硫酸钠干燥, 抽滤蒸干得白色固体, 乙醚洗涤得目标产品。 实施例 6 Add 53 g of 2-chloro-5-oxobicyclo[2.2.1]heptane-7-carboxylic acid to the reaction flask, and add 2000 ml of acetone-water mixed solvent, then gradually add OXONE 150 g, stir the reaction at room temperature, TLC No obvious residue of raw materials was detected. The reaction was quenched by adding NaHS0 3 , the reaction solution was warmed up, some of the solvent was distilled off, stirring was continued, the temperature was lowered, 10% NaOH was added dropwise to make alkali, the reaction was continued, concentrated hydrochloric acid was added to adjust the acidity, and stirring was continued. The reaction mixture was concentrated under reduced pressure. Example 6
5-羟基 -六氢 -2-氧代 -2 -环戊并 [b]呋喃 -4-羧酸的制备 Preparation of 5-hydroxy-hexahydro-2-oxo-2-cyclopenta[b]furan-4-carboxylic acid
于反应瓶依次加入 2-氯 -5-氧代双环 [2.2.1]庚垸 -7-羧酸 35 g,水 1000 ml后, 再逐渐加入 OXONE 135 g, 升温至 40〜50°C, 反应过夜, TLC 检测至无明显原料残余, 加入亚硫酸氢钠淬灭反应, 继续搅拌反应, 滴 加 10% KOH, 调至碱性, 搅拌反应, 加入浓盐酸调 PH值至酸性, 搅 拌反应, 减压浓缩反应液, 以 THF: AcOEt(l :l,V/V)提取, 无水硫酸钠 干燥, 抽滤蒸干得白色固体, 丙酮-石油醚醚重结晶得白色晶体。 实施例 7 Add 35 g of 2-chloro-5-oxobicyclo[2.2.1]heptan-7-carboxylic acid to the reaction flask in turn, 1000 ml of water, then gradually add OXONE 135 g, and raise the temperature to 40~50 °C. Overnight, TLC detected no obvious residue of raw materials, quench the reaction by adding sodium hydrogen sulfite, continue to stir the reaction, add 10% KOH, adjust to alkaline, stir the reaction, add concentrated hydrochloric acid to adjust the pH to acidity, stir the reaction, reduce The reaction mixture was concentrated, dried with EtOAc EtOAc EtOAc (EtOAc) Example 7
5-羟基 -六氢 -2-氧代 -2 -环戊并 [b]呋喃 -4-羧酸的制备 Preparation of 5-hydroxy-hexahydro-2-oxo-2-cyclopenta[b]furan-4-carboxylic acid
于反应瓶依次加入 2-氯 -5-氧代双环 [2.2.1]庚垸 -7-羧酸 40 g, 甲醇- 水混合溶剂 1500 ml后,再逐渐加入 OXO1 E160 g,室温搅拌反应, TLC 检测至无明显原料残余, 加入亚硫酸氢钠淬灭反应, 反应液升温蒸除部 分溶剂, 继续搅拌, 降温, 滴加.10%NaOH碱化, 继续反应, 加入浓盐 酸调 PH值至酸性, 反应液减压浓缩, 以 THF提取, 分出有机层, 无水 硫酸钠干燥, 抽滤蒸干得白色固体, 丙酮-石油醚重结晶得白色物体。 Add 40 g of 2-chloro-5-oxobicyclo[2.2.1]heptan-7-carboxylic acid to the reaction flask, and then add 1500 ml of a methanol-water mixed solvent, then gradually add OXO1 E160 g, and stir the reaction at room temperature, TLC. No obvious residue of raw materials was detected. The reaction was quenched by adding sodium hydrogen sulfite. The reaction solution was heated to evaporate part of the solvent, stirring was continued, the temperature was lowered, and the reaction was continued by adding 10% NaOH. The reaction was continued, and the pH was adjusted to be acidic by adding concentrated hydrochloric acid. The reaction mixture was concentrated under reduced pressure. EtOAc was evaporated, evaporated, evaporated.
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910028164.4 | 2009-01-20 | ||
| CN200910028164.4A CN101525322B (en) | 2009-01-20 | 2009-01-20 | New technology for synthesizing Corey lactonic acid by one-pan boiling method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2010083722A1 true WO2010083722A1 (en) | 2010-07-29 |
Family
ID=41093417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2010/000058 Ceased WO2010083722A1 (en) | 2009-01-20 | 2010-01-13 | A process for one-pot synthesis of corey lactone |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN101525322B (en) |
| WO (1) | WO2010083722A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112680497A (en) * | 2020-12-31 | 2021-04-20 | 南京赛信生物科技有限公司 | Method for separating prostanoid drug key intermediate (1S,5R) -Corey lactone by using biological enzyme |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101525322B (en) * | 2009-01-20 | 2014-04-16 | 中国药科大学 | New technology for synthesizing Corey lactonic acid by one-pan boiling method |
| CN102206224B (en) * | 2011-03-23 | 2013-06-26 | 北京洛斯顿精细化工有限公司 | Method for preparing (1aR,2aS, 5aS,5bS)-tetrahydro-1aH-epoxy [2',3':3,4] cyclopentano [1,2-b] furan-4(5bH)-ketone |
| CN108993354A (en) * | 2018-07-03 | 2018-12-14 | 南京拉艾夫医药科技有限公司 | A kind of synthesizer and synthesis technology of Corey lactone |
| CN110078613B (en) * | 2019-05-31 | 2022-04-22 | 杭州科耀医药科技有限公司 | Synthesis method of 2-halogen-5-iodobenzoic acid |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3952019A (en) * | 1973-05-15 | 1976-04-20 | Imperial Chemical Industries Limited | Bicyclo-octane derivatives |
| US3992438A (en) * | 1973-10-24 | 1976-11-16 | Pfizer Inc. | Novel prostaglandin intermediates |
| CS216027B1 (en) * | 1980-11-27 | 1982-10-29 | Ivan Stibor | Method of making the +l3a alpha,4beta,5alpha,6a alpha+phexahydro-5-acyloxy-4-carboxy-2h-cyclopenta+lb+pfuran-2-on |
| CN101525322A (en) * | 2009-01-20 | 2009-09-09 | 中国药科大学 | New technology for synthesizing Corey lactonic acid by pan boiling method |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7511168B2 (en) * | 2006-01-18 | 2009-03-31 | Shih-Yi Wei | Processes and intermediates for the preparations of prostaglandins |
-
2009
- 2009-01-20 CN CN200910028164.4A patent/CN101525322B/en active Active
-
2010
- 2010-01-13 WO PCT/CN2010/000058 patent/WO2010083722A1/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3952019A (en) * | 1973-05-15 | 1976-04-20 | Imperial Chemical Industries Limited | Bicyclo-octane derivatives |
| US3992438A (en) * | 1973-10-24 | 1976-11-16 | Pfizer Inc. | Novel prostaglandin intermediates |
| CS216027B1 (en) * | 1980-11-27 | 1982-10-29 | Ivan Stibor | Method of making the +l3a alpha,4beta,5alpha,6a alpha+phexahydro-5-acyloxy-4-carboxy-2h-cyclopenta+lb+pfuran-2-on |
| CN101525322A (en) * | 2009-01-20 | 2009-09-09 | 中国药科大学 | New technology for synthesizing Corey lactonic acid by pan boiling method |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112680497A (en) * | 2020-12-31 | 2021-04-20 | 南京赛信生物科技有限公司 | Method for separating prostanoid drug key intermediate (1S,5R) -Corey lactone by using biological enzyme |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101525322B (en) | 2014-04-16 |
| CN101525322A (en) | 2009-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CZ291440B6 (en) | Method for the preparation of citalopram | |
| WO2010083722A1 (en) | A process for one-pot synthesis of corey lactone | |
| JP2560360B2 (en) | Method for producing (+)-biotin | |
| WO2009121791A1 (en) | CONVERSION OF TRYPTOPHAN INTO ß-CARBOLINE DERIVATIVES | |
| EP2168963A1 (en) | Process for the preparation of vinpocetine and apovincamine | |
| CN112679411B (en) | Preparation method of chiral 5- (methylamino) hexahydrocyclopenta [ c ] pyrrole-2 (1H) -Boc methanesulfonate | |
| EP0107693A1 (en) | 2,3,4-TRINOR-1,5-INTER-M-PHENYLENE PROSTACYCLIN I2 ANALOGS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS. | |
| CN113999164A (en) | Preparation method of halofuginone intermediate trans-N-benzyloxycarbonyl- (3-hydroxy-2-piperidyl) -2-acetone | |
| US5446166A (en) | Preparation of pyrrol and oxazole compounds: formation of porphyrins and C-acyl-α-amino acid esters therefrom | |
| JPH04330070A (en) | Preparation of labdane compound | |
| JPS62201842A (en) | Manufacture of 3-hydroxycyclopent-4-ene-1-ones | |
| US6861525B2 (en) | Process for the preparation imidazo[1,2-A]pyridine-3-acetamides | |
| EP0101004B1 (en) | Process for preparing 4-oxo-4, 5, 6, 7-tetrahydroindole derivative | |
| CN113024433A (en) | Preparation method of amisulpride sulfoxide impurities | |
| JPH03279348A (en) | Production of 2,4,5-trifluoro-3-alkoxybenzoic acid | |
| CN113045475A (en) | Preparation method of 5-bromo-7-methylindole | |
| CN118666838B (en) | Asymmetric synthesis method of 1, 1-disubstituted-tetrahydro-beta-carboline derivative | |
| JP7716833B2 (en) | Edoxaban toluenesulfonate intermediate and its manufacturing method | |
| CN104230782A (en) | Synthetic method of silodosin | |
| JP4471664B2 (en) | Process for the preparation of 2- (7-chloro-1,8-naphthyridin-2-yl) -3- (5-methyl-2-oxo-hexyl) -1-isoindolinone | |
| US6403817B1 (en) | Method for preparing prostaglandin E-type compound | |
| CN113754623A (en) | Preparation method of treprostinil intermediate | |
| CN119735539A (en) | A 4-oxopyrrolidine derivative and its preparation method and application | |
| WO2025124470A1 (en) | Doravirine intermediate, and use thereof and synthesis method therefor | |
| WO2025152131A1 (en) | PREPARATION METHOD FOR MONOCYCLIC β-LACTAM COMPOUND |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10733195 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 10733195 Country of ref document: EP Kind code of ref document: A1 |